The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_206933.2(USH2A):c.1036A>C (p.Asn346His)

CA262054

48347 (ClinVar)

Gene: USH2A
Condition: Usher syndrome
Inheritance Mode: Autosomal recessive inheritance
UUID: 211c3a9c-3789-42d9-ab55-04892c95f534
Approved on: 2018-09-14
Published on: 2019-07-17

HGVS expressions

NM_206933.2:c.1036A>C
NM_206933.2(USH2A):c.1036A>C (p.Asn346His)
NC_000001.11:g.216325412T>G
CM000663.2:g.216325412T>G
NC_000001.10:g.216498754T>G
CM000663.1:g.216498754T>G
NC_000001.9:g.214565377T>G
NG_009497.1:g.102985A>C
NM_007123.5:c.1036A>C
NM_206933.3:c.1036A>C
ENST00000307340.7:c.1036A>C
ENST00000366942.3:c.1036A>C
More

Pathogenic

Met criteria codes 5
PP1_Strong PM3_Very Strong PP4 PP3 PM2_Supporting
Not Met criteria codes 18
PVS1 BA1 BS2 BS1 BS4 BP5 BP7 BP2 BP4 BP3 PS4 PS2 PS1 PS3 PM6 PM5 PM1 PM4

Evidence Links 7

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hearing Loss VCEP
The allele frequency of the p.Asn346His variant in the USH2A gene is 0.016% (20/126318) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). The p.Asn346His variant in USH2A has been reported to segregate with hearing loss in at least 7 families including 13 family members (PP1_S; 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15241801, 24160897, 22135276, 26969326). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). Computational prediction tools and conservation analysis suggest that the p.Asn346His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP1_S, PM3_VS, PP4, PP3.
Met criteria codes
PP1_Strong
Cosegretation with the phenotype were observed in at least 7 families including 13 affected members. Agree with this code usage. MD

PM3_Very Strong
This could actually be upgraded to PM3_very strong. There are >4 cases of this variant being identified in trans with a known pathogenic variant. I've added more publications below. -MD

PP4
The patiens of compound heterozygotes or homozygotes with the mutation showed retinitis pigmentosa with hearing loss. Enough patients were also tested for the other Usher syndrome genes and found to be negative for changes in them. I also agree. -MD

PP3
Agree. REVEL is >0.7 -MD
PM2_Supporting
I agree. Variant is present in (20/126318) ) 0.00015% Europeans in gnomAD. -MD
Not Met criteria codes
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
I agree. Variant is present in (20/126318) ) 0.00015% Europeans in gnomAD. -MD
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
I agree. Variant is present in (20/126318) ) 0.00015% Europeans in gnomAD. -MD
BS4
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
BP4
Agree. REVEL is >0.7 -MD
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.